Big paydays ahead as Actavis buys Allergan for $219/share

Actavis will pay $66bn in cash and stock for Allergan, which at $219 per share will generate significant returns for the Botox (onabotulinumtoxinA) maker's shareholders, including a multibillion-dollar payday for Allergan's largest shareholder Pershing Square Capital Management.